Alnylam Stands by Heart Disease Treatments Amid AstraZeneca Trial Setback
By Editor • August 30, 2026 • 1 min read
In response to AstraZeneca's disappointing trial results for its heart drug Wainua, Alnylam Pharmaceuticals is defending its own treatments. Analysts expressed concerns that the failure could imply their silencers, like Amvuttra, may not provide additional benefits over existing stabilizer drugs.
Alnylam emphasizes the efficacy of its products as they prepare for the launch of their next-generation treatment, nucresiran.
Source: www.statnews.com
#Alnylam Pharmaceuticals #AstraZeneca #ATTR-CM #heart disease #silencers
